Get the Stockscreener App
11.94
8.94%
0.98
After Hours:
11.76
-0.18
-1.51%
Gossamer Bio Inc stock is traded at $11.94, with a volume of 267.64K.
It is up +8.94% in the last 24 hours and up +6.61% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$10.96
Open:
$11.78
24h Volume:
267.64K
Relative Volume:
0.82
Market Cap:
$72.96M
Revenue:
$55.54M
Net Income/Loss:
$-180.40M
P/E Ratio:
-15.16
EPS:
-0.7877
Net Cash Flow:
$-170.32M
1W Performance:
+4.81%
1M Performance:
+6.61%
6M Performance:
-68.37%
1Y Performance:
-95.01%
1-Day Range:
$11.28
$12.45
1-Week Range:
$9.961
$12.52
52-Week Range:
$9.104
$309.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
11.94 | 65.57M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus
Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus
Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria
Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia
Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz.co
Gossamer Bio Executes Reverse Stock Split and Share Reduction - TipRanks
Gossamer Bio completes 1-for-80 reverse stock split - investing.com
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split - Business Wire
GOSS: Static price chart | Gossamer Bio | US38341P1021 - marketscreener.com
Gossamer Bio: Dividend historical data and projections - marketscreener.com
Gossamer Bio: Performance & Quotes, GOSS Stock Price on Nasdaq Exchange - marketscreener.com
Gossamer Bio Stock (GOSS)Quote Nasdaq - marketscreener.com
Gossamer Bio To Carry Out 1-for-80 Reverse Stock Split On September 11th, 2026 - Moomoo
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - stocktwits.com
Gossamer Bio at Cantor Fitzgerald healthcare conference: filing path in focus - Investing.com Canada
Gossamer Bio Announces 1-for-80 Reverse Stock Split - tipranks.com
Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M - TradingView
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to earnings forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Biotech Gossamer Bio (NASDAQ: GOSS) markets $125M more in private securities - Stock Titan
Gossamer Bio to Present at Cantor Global Healthcare Conference - Yahoo Finance
Gossamer Bio seeks nod for 1.6B-share issuance | GOSS SEC FilingForm PRE 14A - stocktitan.net
Gossamer Bio Stock (GOSS) Opinions on Phase Advancement Catalysts - Moomoo
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress - investing.com
Gossamer Bio (NASDAQ: GOSS) ties CFO’s 5.8M options to seralutinib FDA decision - Stock Titan
Gossamer Bio (NASDAQ: GOSS) ties CCO options to FDA drug decision - Stock Titan
GOSS 4-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Eastern Progress
Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones - sahmcapital.com
Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift - Kalkine Media
Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - pulse2.com
Latham Advises Gossamer Bio on Structured Private Placement - Latham & Watkins LLP
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital - Legal Desire
Gossamer Bio Slips as $250M Financing Hinges on FDA ApprovalGossamer Bio (NASDAQ:GOSS) - Benzinga
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Chall - GuruFocus
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval - citybiz.co
$Gossamer Bio (GOSS.US)$ yessir 🦁 mode still early - Moomoo
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Landscape - GuruFocus
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell - marketscreener.com
Gossamer Bio secures up to $250m in milestone-based financing - Investing.com
$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷♂️ 😉 - Moomoo
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio, Inc. announced that it expects to receive $250 million in funding - marketscreener.com
Revenue per share of Gossamer Bio, Inc. – HAM:4GB - TradingView
Gossamer Bio achieves exceptional financial eff... - Pluang
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):